Navigation Links
Silence Therapeutics Announces Issuance of Japanese Patent for Screening Therapeutics Against Key Pathway Associated with Cancer and Other Diseases
Date:9/16/2011

LONDON, September 16, 2011 /PRNewswire/ --


Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading RNA interference (RNAi) therapeutics company, announces the issuance of patent 4810095 entitled "Use of Protein Kinase N beta" by the Japanese Patent Office. The issued patent covers certain methods for screening a therapeutic agent for the treatment and/or prevention of any disease that involves elevated activity within the PI3-kinase pathway. More specifically, this new intellectual property covers the use of protein kinase N 3 ("PKN3") for screening of therapeutic agents, thus preventing others from using PKN3 for screening purposes. This new patent is broadly directed to various classes of therapeutic agents with the potential to impact the PI3-kinase pathway including short interfering RNA (siRNA) molecules, antibodies and small molecules, among others.  

PKN3 is a protein kinase C-related molecule, involved in the PI3-kinase pathway that is believed to play an important role in the growth of cancer cells, as well as metastasis formation. Silence has built a significant research program around PKN3 and the company's lead clinical compound, Atu027, is an RNAi therapeutic that targets PKN3 for the treatment of advanced solid tumors.  

"We are excited about consolidating our broad patent portfolio in Japan, especially as it pertains to our high-value PKN3 program," said Dr Klaus Giese, chief scientific officer of Silence Therapeutics. "This patent positions Silence as the exclusive gatekeeper for any project focused on developing therapeutics targeting PKN3, and as interest in this important oncology target continues to grow rapidly, we expect the value of this intellectual property position will also increase significantly."

Silence Therapeutics is proactively building and strengthening its global, diverse and competitive intellectual property portfolio. This provides the Company and po
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Silence Therapeutics and InteRNA Technologies Sign Collaboration to Develop Novel microRNA Therapeutics
2. Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
3. Silence Therapeutics Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting
4. Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials
5. Silence Therapeutics Provides Year-end Update
6. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
7. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
8. Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Silence Therapeutics Announces Board Changes
11. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 2015 Insulet Corporation (NASDAQ: PODD ), ... OmniPod ® Insulin Management System, today announced preliminary ... 2015. The Company also announced that it will postpone ... and conference call from Thursday, July 30, as originally ... Highlights: , Preliminary second quarter ...
(Date:7/29/2015)... SANTA MONICA, Calif. , July 29, 2015 /PRNewswire/ ... to the San Diego Marriott Marquis & Marina on ... the medical device industry. A highlight of the Business ... Secure Financial Backing from Different Types of Investors, featuring ... Johnson & Johnson Development Corporation; Brent Ahrens , ...
(Date:7/29/2015)... 29, 2015  According to data released today by ... average monthly Medicare Part D premium is expected to ... was originally projected, the Pharmaceutical Care Management Association (PCMA) ... to be a bright spot in American health care. ... region and using cutting edge, cost-saving tools like pharmacy ...
Breaking Medicine Technology:Insulet Reports Preliminary Second Quarter 2015 Revenue Results 2Insulet Reports Preliminary Second Quarter 2015 Revenue Results 3Insulet Reports Preliminary Second Quarter 2015 Revenue Results 4Insulet Reports Preliminary Second Quarter 2015 Revenue Results 5MEDevice San Diego Offers Tips on Securing Financial Backing from Investors 2
(Date:7/30/2015)... ... 30, 2015 , ... New research finds some distinct differences in the way ... on the Surviving Mesothelioma website. , Researchers with the National Institutes of Health, ... cases of mesothelioma occurring between 1990 and 2010. Two percent of these cases (207) ...
(Date:7/30/2015)... Angeles, California (PRWEB) , ... July 30, 2015 , ... ... August 5th 2015 - “Learn How to Make Money in the Booming Homecare Business.” ... Los Angeles CA 90010. , The event will be hosted by ...
(Date:7/30/2015)... ... 2015 , ... After conducting a nationwide executive search led by healthcare leadership ... Far Rockaway, N.Y., has hired Gerard (Jerry) Walsh as Chief Executive Officer. Walsh assumed ... leadership experience, Walsh is an expert in organizational change, physician development, implementation of quality ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... with its Medicare administrative contractor (MAC) over submitted claims for bariatric surgery that, ... a challenge to program integrity, Becky Dennis, a nurse auditor at WellSpan Health, ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... largest amount of research grants in its history of funding brain aneurysm research. ... who have dedicated their life’s work toward scientific research directed at early detection, ...
Breaking Medicine News(10 mins):Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:Upcoming Business Seminar at 1Heart Caregiver Services Headquarters Los Angeles California 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 3Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 4Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 5Health News:Hospital Details Fight for Bariatric Surgery Reimbursement in AIS Newsletter 2Health News:Hospital Details Fight for Bariatric Surgery Reimbursement in AIS Newsletter 3Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 2Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 3Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 4
... drugs meant for treating HIV patients also served to protect ... the same can be applied to human beings also has ... ,Rhesus monkeys were experimented upon by the ... them with a version of the Truvada, manufactured by Gilead ...
... older adults due to brain related changes, according to ... easy where younger adults are concerned. The healthy middle ... good where concentrating is concerned, according to functional magnetic ... of the Rotman Research Institute at the Baycrest Center ...
... rates of patients, specific for every surgeon in Scotland has ... community. A majority of the surgeons feel that the ... the surgeon, list of hospitals in which the surgeon has ... the associated mortality rate are amongst the details published. The ...
... that there has been an increase in heart failure cases among ... with men surviving for longer periods. There has been a ... to 1994 period when compared to the 1970 to 1974 period, ... the study. ,The chances of heart failure occurring ...
... National Institute of Immunology are reported to have identified ... the tuberculosis (TB) bacteria survives in the human body. ... more effective medicines to combat the disease, which claims ... annually. The research team led by Rajesh S. Gokhale ...
... A team of researchers led by Dr Stephen Harbarth have ... to be useful in reducing the // infection rates ... by the NHS in dealing with the bug. ... in patient swabs. The researchers said that this test was ...
Cached Medicine News:Health News:The Publication Of Surgeon Specific Death Rates Raises Controversy 2
1.5 mm x 12 mm tip. Angled 15 degrees. Teflon coated with diathermy attachment....
2 mm diameter blade. Angled 60 degrees. Sharp. Round handle....
2 mm. Angled 13 degrees, 15 mm from angle to tip. Round handle....
1.25 mm x 2.5 mm blade. 135 degrees back scratcher. Round handle....
Medicine Products: